PMID- 37529870
OWN - NLM
STAT- MEDLINE
DCOM- 20231011
LR  - 20231011
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 25
IP  - 11
DP  - 2023 Nov
TI  - Effects of once-weekly glucagon-like peptide-1 receptor agonists on type 2 
      diabetes mellitus complicated with coronary artery disease: Potential role of the 
      renin-angiotensin system.
PG  - 3223-3234
LID - 10.1111/dom.15219 [doi]
AB  - AIM: To investigate the potential mechanism of once-weekly glucagon-like 
      peptide-1 receptor agonists (GLP-1 RA) in the treatment of type 2 diabetes 
      mellitus (T2DM) complicated with coronary artery disease (CAD). METHODS: We 
      searched both Chinese and English databases for randomized controlled trials 
      related to once-weekly GLP-1 RA for T2DM complicated with CAD to verify the 
      safety and efficacy of GLP-1 RA. The underlying mechanism was analysed by network 
      pharmacology. RESULTS: In total, 13 studies with 35 563 participants were 
      included in the analysis. The pooled analysis found that dulaglutide, exenatide 
      and semaglutide outperformed placebo in cardiovascular outcomes in patients with 
      T2DM, with a significant reduction in the incidence of non-fatal stroke 
      (p < .00). Levels of cardiovascular risk factors were significantly reduced in 
      the once-weekly GLP-1 RA group compared with the conventional treatment group 
      (glycated haemoglobin: p < .00; fasting blood glucose: p < .00; weight: p < .00; 
      systolic blood pressure: p < .00; total cholesterol: p < .00; low-density 
      lipoprotein cholesterol: p < .00). Network pharmacology results were enriched to 
      the renin-angiotensin system, and matrix metalloproteinase 2 and renin (REN) may 
      be the key targets. In addition, four key targets of dulaglutide, five key 
      targets of exenatide and two key targets of semaglutide were enriched. 
      CONCLUSIONS: Our study suggests that once-weekly GLP-1 RA may have a potential 
      protective effect on cardiovascular events in patients with T2DM combined with 
      CAD, possibly through the renin-angiotensin system. However, further research is 
      needed to confirm these findings and determine cause and effect.
CI  - (c) 2023 John Wiley & Sons Ltd.
FAU - Kan, Mengfan
AU  - Kan M
AD  - Teaching and Research Section of Internal Medicine, College of Medicine, Shandong 
      University of Traditional Chinese Medicine; Department of Endocrinology and 
      Metabology, The First Affiliated Hospital of Shandong First Medical University & 
      Shandong Provincial Qianfoshan Hospital; The Third Affiliated Hospital of 
      Shandong First Medical University, Jinan, China.
FAU - Fu, Hui
AU  - Fu H
AD  - Medical Integration and Practice Center, Shandong University, Jinan, China.
FAU - Xu, Yunsheng
AU  - Xu Y
AD  - The Second Affiliated Hospital of Shandong University of Traditional Chinese 
      Medicine, Jinan, China.
FAU - Yue, Zhaodi
AU  - Yue Z
AD  - College of Rehabilitation Medicine, Shandong University of Traditional Chinese 
      Medicine, Jinan, China.
FAU - Du, Bingyu
AU  - Du B
AD  - College of Rehabilitation Medicine, Shandong University of Traditional Chinese 
      Medicine, Jinan, China.
FAU - Chen, Qiang
AU  - Chen Q
AD  - College of Rehabilitation Medicine, Shandong University of Traditional Chinese 
      Medicine, Jinan, China.
FAU - Wang, Xueyin
AU  - Wang X
AD  - Department of Endocrinology and Metabolism, The Third Affiliated Hospital of 
      Shandong First Medical University; Department of Endocrinology and Metabolism, 
      The First Affiliated Hospital of Shandong First Medical University & Shandong 
      Provincial Qianfoshan Hospital; Shandong Key Laboratory of Rheumatic Disease and 
      Translational Medicine, Jinan, China.
FAU - Yu, Shaohong
AU  - Yu S
AD  - Teaching and Research Section of Internal Medicine, College of Medicine, Shandong 
      University of Traditional Chinese Medicine, Jinan, China.
AD  - Department of Rehabilitation Medicine, The Second Affiliated Hospital of Shandong 
      University of Traditional Chinese Medicine, Jinan, China.
FAU - Zhang, Zhongwen
AU  - Zhang Z
AUID- ORCID: 0000-0001-8490-5074
AD  - Department of Endocrinology and Metabolism, The Third Affiliated Hospital of 
      Shandong First Medical University; Department of Endocrinology and Metabolism, 
      The First Affiliated Hospital of Shandong First Medical University & Shandong 
      Provincial Qianfoshan Hospital; Shandong Key Laboratory of Rheumatic Disease and 
      Translational Medicine, Jinan, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20230802
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 97C5T2UQ7J (Cholesterol)
RN  - 9P1872D4OL (Exenatide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - 0 (Hypoglycemic Agents)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
SB  - IM
MH  - Humans
MH  - Cholesterol
MH  - *Coronary Artery Disease/complications/drug therapy
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Exenatide/therapeutic use
MH  - Glucagon-Like Peptide 1/therapeutic use
MH  - *Glucagon-Like Peptide-1 Receptor/agonists
MH  - Glucagon-Like Peptides
MH  - Hypoglycemic Agents/adverse effects
MH  - Matrix Metalloproteinase 2
MH  - Renin-Angiotensin System
OTO - NOTNLM
OT  - coronary artery disease
OT  - meta-analysis
OT  - network pharmacology
OT  - once-weekly GLP-1 receptor agonists
OT  - renin-angiotensin system
OT  - type 2 diabetes mellitus
EDAT- 2023/08/02 06:42
MHDA- 2023/10/04 06:44
CRDT- 2023/08/02 04:14
PHST- 2023/06/08 00:00 [revised]
PHST- 2023/01/27 00:00 [received]
PHST- 2023/07/04 00:00 [accepted]
PHST- 2023/10/04 06:44 [medline]
PHST- 2023/08/02 06:42 [pubmed]
PHST- 2023/08/02 04:14 [entrez]
AID - 10.1111/dom.15219 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2023 Nov;25(11):3223-3234. doi: 10.1111/dom.15219. Epub 2023 
      Aug 2.